Herein, we performed an HTS of SHP099, a specific SHP2 inhibitor with limited off-target effects (24), across hundreds of tumor-derived cell lines and found that HNSCC models were among the most sensitive. The gene discussed is PTPN11; the disease is head and neck squamous cell carcinoma.